DEF: Organogenesis Holdings Inc. Announces 2025 Annual Meeting of Stockholders, Proposes Director Re-election and Nasdaq Proposal

Organogenesis Holdings Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 23, 2025, to vote on director re-election, executive compensation, a Nasdaq proposal, and auditor ratification.

Summary

• Organogenesis Holdings Inc. is holding its 2025 Annual Meeting of Stockholders on June 23, 2025, virtually.
• Stockholders will vote on the re-election of nine directors, an advisory vote on executive compensation, a Nasdaq proposal regarding the issuance of common stock upon conversion of preferred stock, and the ratification of the appointment of RSM US LLP as the independent registered public accounting firm for fiscal year 2025.
• The Nasdaq proposal seeks approval for the issuance of common stock exceeding 20% of the company's outstanding shares upon conversion of Series A Convertible Preferred Stock.
• The board of directors recommends voting for all director nominees, the advisory vote on executive compensation, the Nasdaq proposal, and the ratification of the auditor appointment.
• Holders of record as of April 28, 2025, are entitled to vote.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/ORGO2025.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive sentiment. The company is taking steps to secure its financial future and ensure good corporate governance.

Positives

• The board is recommending a vote FOR all director nominees.
• The board is recommending a vote FOR the advisory vote on executive compensation.
• The board is recommending a vote FOR the Nasdaq proposal.
• The board is recommending a vote FOR the ratification of RSM US LLP as the independent registered public accounting firm.

Negatives

• Approval of the Nasdaq proposal will result in dilution of current stockholders' percentage ownership.
• If the Nasdaq Proposal is not approved, the company will be required to incur additional costs in order to hold additional stockholder meetings on a semi-annual basis to seek such approval until such approval is obtained as is required under the Subscription Agreement.
• If the Nasdaq Proposal is not approved, the company will be required to make Cash-in-Lieu payments to Avista in the event Avista elects to convert the Convertible Preferred Stock to Common Stock and such conversion would result in the issuance of shares of Common Stock exceeding 19.99% of our outstanding shares of Common Stock.

Risks

• Failure to approve the Nasdaq proposal could hinder the company's ability to issue common stock upon conversion of preferred stock.
• The conversion of preferred stock could result in significant dilution for existing stockholders.
• The company may be required to make cash-in-lieu payments if the Nasdaq proposal is not approved and Avista converts preferred stock.
• The company's reliance on a small group of stockholders for voting power could present governance risks.

Future Outlook

The company intends to use the net proceeds from the private placement to fund strategic growth initiatives, including operating and commercial activities, clinical development programs, working capital, capital expenditures, debt repayment, and for general corporate purposes.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy solicitations, director elections, and executive compensation disclosures. The Nasdaq proposal highlights the complexities of raising capital while adhering to exchange listing rules.

Comparison to Industry Standards

• The director compensation structure, including retainers and committee fees, is generally in line with industry standards for companies of similar size and complexity.
• The use of independent compensation consultants to benchmark executive pay is a common practice among publicly traded companies.
• The change in control retention agreements with double-trigger provisions are consistent with market practices to protect executives during potential acquisitions.
• The company's clawback policy aligns with the requirements of the Dodd-Frank Act and Nasdaq listing rules.

Related Party Transactions

• The company leases buildings from entities controlled by significant stockholders, with aggregate payments totaling several million dollars in 2024.
• The company repurchased shares of common stock from certain existing stockholders, including directors and their affiliates, for a total of $25.5 million.
• Gary Gillheeney, Jr., son of the CEO, is employed as Vice President, Customer Experience, and received total compensation of $406,643 in fiscal year 2024.
• James Gillheeney, son of the CEO, is employed as a regional sales manager, and received total compensation of $268,973 in fiscal year 2024.

Stakeholder Impact

• Approval of the Nasdaq proposal could dilute the ownership of existing shareholders.
• The outcome of the executive compensation vote could influence future compensation practices.
• The election of directors will shape the company's leadership and strategic direction.
• The ratification of the auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting of Stockholders on June 23, 2025.
• The company will await the results of the stockholder vote on the Nasdaq proposal.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Nasdaq Proposal, Auditor Ratification, Convertible Preferred Stock, Common Stock, RSM US LLP, Organogenesis